SummaryThis collection contains a small subset of ACRIN 6684 trial data intended for use in Quantitative Imaging Network (QIN) projects. Additional follow-up scans which were not part of the ACRIN trial are provided by Mark Muzi and Dr. James Fink from University of Washington. Each study contains DCE, DSC, DTI and BOLD imaging data along with the conventional imaging (T1, T2, FLAIR, MPRAGE). The MR data was collected on a Philips Achieva 3T MR. Acquisition sequences and the patient cohort are described further in the Detailed Description tab below. Funding sources for this data set include: P01-CA042045 (Mark Muzi), UW U01-CA148131 (Paul E. Kinahan) and GERRAF (James R. Fink), ACRIN U01 CA080098, ACRIN U01 CA079778.
About the NCI QIN
The mission of the QIN is to improve the role of quantitative imaging for clinical decision making in oncology by developing and validating data acquisition, analysis methods, and tools to tailor treatment for individual patients and predict or monitor the response to drug or radiation therapy. More information is available on the Quantitative Imaging Network Collections page. Interested investigators can apply to the QIN at: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01) PAR-11-150.
This is a limited access data set. To request access, please contact firstname.lastname@example.org. Once access is granted, you can view and download these images on The Cancer Imaging Archive (TCIA) by logging in and selecting the QIN GBM DCE-MRI collection.
Click the Versions tab for more info about data releases.
Number of Patients
Number of Studies
Number of Series
Number of Images
|Images Size (GB)||22.7|
- Diffusion Tensor Imaging (DTI): Echoplanar spin-echo pulse sequence; TR/TE 7459/69ms; 220x220x144mm FOV; 128x128x72 slice matrix; 1.72x1.72x2.0mm voxels; sense factor 2.5 in the AP direction, 32 directions; 0 and 1000 bvalues; diffusion timing ∆ 34.2ms;
- T1 mapping: 3D gradient echo pulse sequence; TR/TE 5.2/2.5ms; 256x168x59.2mm FOV; 1.0x1.64x3.7mm voxels; 256x102x16 slice matrix; sense factor 2 in the AP direction; 2,10,15,20,30 degree flip angles. T1 MAP images for the DCE data were created using Kyung Sung’s DCE Tool Osirix plug-in, following rescaling of the flip angle images. Philips is non-DICOM compliant and puts the correct scale factors in private DICOM fields (slope 2005,100e and intercept 2005,100d).
- T1 Dynamic Contrast Enhanced imaging (DCE): 3D gradient echo pulse sequence; TR/TE 5.2/2.5ms; 256x168x59.2mm FOV; 1.0x1.64x3.7mm voxels; 256x102x16 slice matrix; sense factor 2 in the AP direction; 20 degree flip angle, 60 dynamic scans at 5.5 second interval. Contrast agent was 16.2ml of Prohance.
- T2 Dynamic susceptibility contrast imaging (DSC): echoplanar gradient echo pulse sequence; TR/TE 1500/30ms; 220x220x74mm FOV; 1.72x1.72x3.7mm voxels; 128x128x20 slice matrix; sense factor 2 in the AP direction; 75 degree flip angle; 120 dynamic scans at 1.5 second interval.
- BOLD Imaging Protocol: BOLD and ASL sequences were acquired simultaneously giving BOLD and flow images at the same time acquired over a scan time of approximately 15 min. BOLD MRI was acquired during transient inhalation of 100% oxygen in the magnet using the following oxygen breathing procedure:
- Room air for 8 minutes
- 100% FiO2 hyperoxia for 4 minutes
- Room air for 2 minutes.
There are repeat studies for each of 10 patients (36 studies total) to allow examination of analysis methodology, algorithm design and validation of results. Thus only a small portion (4 baseline imaging studies) were part of the ACRIN 6684 cohort. These 10 patients are a subset of a larger collection that have yet to be published. Pathology and outcome data for the group of 10 are provided (GBM = glioblastoma multiforme, AA = astrocytic astrocytoma, GC = gliomatosis cerebri). The study dates and the date of pathological diagnosis are provided. Baseline scans were just prior to conventional chemo-radiation (Rx = RT+TMZ), earlyRx was usually after 1 cycle, lateRx was before completion, postRx was following therapy and an additional study was acquired if recurrence was observed by standard clinical criteria. All patients in the cohort had at least a pre and a post conventional therapy (RT+TMZ) scan. This information is summarized in the patient diagnosis spreadsheet: QIN-GBM-DCE-MRI Patient Table.xlsx.
Citations & Data Usage Policy
This is a limited access data set. Upon receiving access you may only use it for the purposes outlined in your request to the data provider. You are not allowed to redistribute the data or use it for other purposes. See TCIA's Data Usage Policies and Restrictions for additional details. Questions may be directed to email@example.com.
Please be sure to include the following citations in your work if you use the data set:
Mark Muzi, Elizabeth Gerstner, James R. Fink. (2016). Data From QIN GBM DCE-MRI. The Cancer Imaging Archive. http://doi.org/10.7937/K9/TCIA.2016.aWorz1Fq
Primary paper citation coming soon.
Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, Prior F. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository, Journal of Digital Imaging, Volume 26, Number 6, December, 2013, pp 1045-1057. (paper)
Other Publications Using This Data
- Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Mintz A, Kostakoglu L, Eikman EA, Prah MA, Ellingson BM, Ratai EM, Schmainda KM, Sorensen G, Barboriak DP, Mankoff DA. ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using 18F-FMISO PET and MRI. Clin Cancer Res 2016. Accepted.
- Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Mintz A, Kostakoglu L, Eikman EA, Prah M, Schmainda KM, Sorensen GA, Barboriak D, Mankoff DA. ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBM using 18F-FMISO PET and MRI. J Clin Oncol 33(Suppl):2024. 2015.
- Fink JR, Zhang Z, Gerstner ER, Muzi M, Kostakoglu L, Mintz A, Eikman EA, Barboriak D, Mankoff DA. ACRIN 6684: Multicenter phase II assessment of tumor hypoxia in glioblastoma using 18F-Fluoromisonidazole (FMISO) PET and MRI. J Nucl Med 56(Suppl3):325. 2015.
- Fink JR, Muzi M, Peck M, Krohn KA. Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging. J Nucl Med 56(10):1554-1561. 2015.
- Muzi M, Fink JR, Richards TL, Marro KI, Wong T, Muzi JP, Eary JF, Rockhill JK, Krohn KA. Evaluation of PET and MR measurements to examine progression in glioma patients. J Nucl Med 55(Suppl1):1512-. 2014.
- No labels